PolyMedix Reschedules Webcast for Wednesday, April 7 at 10:00 AM

Management to Review Results from Phase 1B Clinical Study with Novel Antibiotic,
PMX-30063
RADNOR, Pa.--(Business Wire)--
PolyMedix, Inc. (OTC BB: PYMX), an emerging bio-technology company focused on
developing new therapeutic drugs to treat acute cardiovascular disorders and
infectious diseases, has rescheduled its webcast for Wednesday, April 7 at 10:00
AM Eastern Time. At that time, management will review the results from the
recently completed Phase 1B clinical study with PMX-30063, PolyMedix`s novel
defensin-mimetic antibiotic.

A live webcast may be accessed on PolyMedix`s website at www.polymedix.com or at
http://investor.shareholder.com/media/eventdetail.cfm?eventid=79828&CompanyID=ABEA-4ITCYZ&e=1&mediaKey=AA30477493DD80F026CCF4C7874D5D89.
An archive of the event will be available on either site approximately two-hours
after the event.

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development
of novel drugs and biomaterials for the treatment of acute cardiovascular
disorders and infectious diseases. PolyMedix`s compounds are based on
biomimetics: non-peptide small molecule drug candidates and polymers that mimic
the activity of proteins. PMX-60056, PolyMedix`s heptagonist compound, is being
developed to reverse the activity of both heparin and low molecular weight
heparins. PolyMedix plans to develop an antagonist drug that is safer and easier
to use than currently approved therapy. PMX-30063, PolyMedix`s antibiotic
compound is a small molecule that mimics human host-defense proteins and has a
completely different mechanism of action distinct from those of current
antibiotic drugs, a mechanism which is intended to make bacterial resistance
unlikely to develop. PolyMedix`s goal is to develop this compound as a rapidly
acting antibiotic for serious systemic and local infections. Both PMX-60056
heptagonist and PMX-30063 antibiotic are currently undergoing clinical testing.
PolyMedix also plans to continue the development of polymeric formulations as
antimicrobial biomaterials, which can be used as additives to paints, plastics,
and textiles to create self-sterilizing products and surfaces. For more
information, please visit PolyMedix on its website at www.polymedix.com.

This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995 that
involve risks, uncertainties and assumptions that could cause PolyMedix`s actual
results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. PolyMedix has in
some cases identified forward-looking statements by using words such as
"anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans,"
"intends," "goal," "potential," "may," "suggest," and similar expressions. Among
other factors that could cause actual results to differ materially from those
expressed in forward-looking statements, PolyMedix`s compounds may not enter or
successfully complete clinical testing, or be granted regulatory approval to be
sold and marketed in the United States or elsewhere. A more complete description
of these risk factors is included in PolyMedix`s filings with the Securities and
Exchange Commission. You should not place undue reliance on any forward-looking
statements. PolyMedix undertakes no obligation to release publicly the results
of any revisions to any such forward-looking statements that may be made to
reflect events or circumstances after the date of this press release or to
reflect the occurrence of unanticipated events, except as required by applicable
law or regulation.

PolyMedix, Inc.
Lisa Caperelli
Director, Investor Relations & Corporate Communications
484-598-2406
lcaperelli@polymedix.com
or
Investor Relations Group, Inc.
Investors:
Erika Moran
emoran@investorrelationsgroup.com
or
Media:
Janet Vasquez
jvasquez@investorrelationsgroup.com
212-825-3210

Copyright Business Wire 2010